Diphenhydramine

At 25-50 mg -- the dose printed on the box -- diphenhydramine is boring. A heaviness settles over the eyelids within thirty to forty-five minutes. The body feels warm and slightly leaden. Allergies quiet down. You get sleepy. That is, genuinely, the entire experience for the vast majority of people who take it as directed. The drowsiness is not pleasant the way an opioid nod is pleasant; it is more like someone turning down a dimmer switch on your alertness.

At 150-250 mg, the experience shifts in character. Drowsiness becomes extreme -- a thick, sticky exhaustion that makes holding your eyes open feel like a physical feat, yet actual restful sleep becomes paradoxically elusive. There is a pronounced body load: heavy limbs, dry mouth that no amount of water seems to fix, a noticeable increase in heart rate. Vision blurs. Coordination deteriorates. The mental state is foggy and confused rather than altered in any interesting way. Most people who experiment at this dose report that it felt like being sick -- feverish, disoriented, and deeply uncomfortable.

At 300-700 mg -- the doses that the r/DPH community documents -- the anticholinergic delirium begins, and this is where diphenhydramine distinguishes itself from every other class of psychoactive substance. There are no geometric patterns, no color enhancement, no euphoria, no sense of cosmic meaning. Instead, the hallucinations arrive as mundane, utterly convincing fabrications that you do not recognize as hallucinations while they are happening.

The most universally reported hallucination is "shadow people" -- dark humanoid figures standing in doorways, sitting in corners, or walking past the periphery of vision. Users describe spiders and insects crawling on walls, across skin, across bedsheets -- so real that they try to brush them off. There are phantom cigarettes: you reach down, pick one up, bring it to your lips, and it dissolves because it was never there. You hear someone knocking on the door. You hear your name called from another room. You pick up your phone and have a text conversation that you later discover never happened. One of the most characteristic and disturbing features is holding a coherent conversation with a person -- a friend, a parent, a stranger -- only to look up and find the room empty. Users describe these episodes not with the detached fascination of a psychedelic trip report but with genuine horror. You are not "tripping." You are losing your ability to distinguish reality from fabrication, and you may not regain it for hours.

The physical experience at these doses is profoundly unpleasant. Heart rate climbs to 120-150 bpm. The mouth is so dry that swallowing becomes difficult. Vision is too blurred to read a phone screen. The body feels simultaneously restless and paralyzed -- a jittery, agitated heaviness that users call "restless legs on your entire body." Urination becomes difficult or impossible. Body temperature rises. There is a sense of gravity being wrong, of weight shifting unpredictably. The overall feeling, described with remarkable consistency across thousands of reports, is dysphoric dread. Not fear of something specific, but a pervasive, ambient wrongness that saturates the entire experience.

Coming down takes many hours. The delirium fades in waves -- you regain the ability to recognize that you are intoxicated, the shadow people recede, the phantom objects stop appearing. But a thick cognitive fog lingers well into the next day, often accompanied by a headache, sore muscles, and an emotional flatness that users describe as feeling "emptied out."

Mechanism of Action

Diphenhydramine is classified as a first-generation antihistamine, but calling it "just" an antihistamine undersells its pharmacological complexity. The molecule acts on at least four major receptor systems, and the balance between these actions determines whether you experience mild drowsiness or full-blown delirium.

At the H1 histamine receptor, diphenhydramine functions as an inverse agonist -- not merely blocking histamine from binding (as a neutral antagonist would), but actively reducing constitutive receptor activity below baseline. This distinction matters clinically: inverse agonism suppresses allergic signaling more potently than simple antagonism. Because first-generation antihistamines like diphenhydramine are lipophilic enough to freely cross the blood-brain barrier, they act on central H1 receptors involved in wakefulness, which is why drowsiness is the most reliable effect and why diphenhydramine became the backbone of OTC sleep aids.

The Anticholinergic Mechanism

The deliriant properties of diphenhydramine arise from its potent antagonism at muscarinic acetylcholine receptors (mAChRs), particularly the M1 subtype that dominates cortical and hippocampal neurons. Acetylcholine is the neurotransmitter most directly associated with attention, memory consolidation, and the brain's ability to distinguish internally generated signals from external sensory input. When diphenhydramine floods muscarinic receptors at supratherapeutic doses, this reality-monitoring system collapses. The brain can no longer differentiate between its own spontaneous neural activity and genuine perceptual input -- which is why anticholinergic hallucinations feel absolutely real in a way that serotonergic psychedelic visuals do not.

The clinical presentation at high doses follows the classic anticholinergic toxidrome, taught to medical students as a mnemonic: "Blind as a bat (mydriasis, cycloplegia), mad as a hatter (delirium, hallucinations), red as a beet (cutaneous vasodilation), hot as a hare (hyperthermia from suppressed sweating), dry as a bone (anhidrosis, xerostomia), the bowel and bladder lose their tone (ileus, urinary retention), and the heart runs alone (tachycardia)."

Additional Receptor Activity

Beyond H1 and muscarinic receptors, diphenhydramine acts on several other targets:

• Sodium channel blockade -- At high doses, diphenhydramine inhibits cardiac sodium channels in a manner similar to class Ia antiarrhythmic drugs, which is the mechanism behind its cardiotoxicity: QRS widening, QT prolongation, and potentially fatal arrhythmias
• Serotonin reuptake inhibition -- Modest SRI activity, which is why diphenhydramine can precipitate serotonin syndrome when combined with SSRIs, MAOIs, or other serotonergic drugs at high doses
• Dopamine reuptake inhibition -- Weak but present, which may partly explain the restless dysphoria rather than sedation that some users report at high doses
• Opioid receptor activity -- Very weak mu-opioid affinity that is clinically insignificant at standard doses

Pharmacokinetics

Diphenhydramine is well-absorbed orally with a bioavailability of approximately 40-60% due to significant first-pass hepatic metabolism. Peak plasma concentrations are reached within 2-3 hours. The drug is extensively metabolized by CYP2D6, with an elimination half-life of 4-8 hours in healthy adults but extending to 9-18 hours in the elderly -- a critically important detail given that older adults are both more likely to take it regularly and more susceptible to its anticholinergic cognitive effects. Metabolites are excreted renally.

Synthesis and Early Approval

Diphenhydramine was first synthesized in 1943 by George Rieveschl, a chemical engineer and professor at the University of Cincinnati. Rieveschl was not specifically searching for an antihistamine -- he was investigating ethanolamine compounds as potential antispasmodics. When one of his compounds showed powerful antihistaminic activity, he recognized its clinical potential. Parke-Davis licensed the molecule and brought it through clinical trials.

In 1946, diphenhydramine became one of the first antihistamines approved by the FDA, initially available only by prescription. Parke-Davis marketed it under the brand name Benadryl -- a name that would become so ubiquitous that it entered everyday language as a generic term for allergy medicine, much the way "Aspirin" had for acetylsalicylic acid a generation earlier.

Becoming Over-the-Counter

Through the 1950s and 1960s, diphenhydramine established itself as one of the most commercially successful drugs in American pharmacy. Its dual action -- treating allergies and inducing sleep -- gave it an unusually broad market. In 1982, the FDA approved diphenhydramine for over-the-counter sale, a move that reflected decades of safety data at recommended doses and dramatically expanded access. It was subsequently incorporated into dozens of combination products: Tylenol PM, Advil PM, ZzzQuil, Unisom SleepGels, and countless store-brand equivalents. By the 2000s, diphenhydramine was present in more OTC formulations than almost any other active ingredient in the United States.

The WHO Essential Medicines List

The World Health Organization added diphenhydramine to its Model List of Essential Medicines, recognizing it as one of the most important medications needed in a basic health system. This listing reflected its genuine therapeutic value as an antihistamine, antiemetic, and treatment for anaphylaxis -- a life-threatening allergic reaction where diphenhydramine serves as an adjunct to epinephrine.

Emergence of Recreational Misuse

Intentional misuse of diphenhydramine for its deliriant properties is not a new phenomenon -- case reports in the medical literature stretch back to the 1960s and 1970s, often involving psychiatric inpatients or adolescents with limited access to other substances. But the internet fundamentally changed the scale and visibility of DPH misuse. Beginning in the early 2000s, forums like Erowid, Bluelight, and later Reddit became repositories for detailed trip reports. The r/DPH subreddit, which grew steadily through the 2010s, created an unprecedented public archive of anticholinergic delirium experiences -- simultaneously serving as a harm reduction resource and, critics argued, a normalizing force.

The Benadryl Challenge and Public Health Response

In May 2020, a trend dubbed the "Benadryl Challenge" began circulating on TikTok, encouraging teenagers to take large doses of diphenhydramine to induce hallucinations and film the results. The trend led to a wave of hospitalizations across the United States. In September 2020, the FDA issued a formal safety warning about the dangers of high-dose diphenhydramine, and Johnson & Johnson (which had acquired the Benadryl brand through its purchase of Pfizer's consumer health division) worked with TikTok to remove related content. At least one death -- a 15-year-old in Oklahoma -- was attributed directly to the challenge. The episode highlighted a paradox unique to diphenhydramine: a substance too dangerous for recreational use at high doses, yet too medically valuable and too widely available to restrict.

The Dementia Controversy

In 2015, a prospective cohort study led by Shelly Gray at the University of Washington, published in JAMA Internal Medicine, tracked 3,434 participants aged 65 and older for an average of 7.3 years. The study found that higher cumulative anticholinergic use -- with diphenhydramine being one of the most commonly used anticholinergics -- was associated with a statistically significant, dose-dependent increase in dementia risk. Participants in the highest exposure category had a 54% greater risk of developing dementia. While the study could not establish causation, its size, prospective design, and the biological plausibility of the mechanism (chronic muscarinic blockade impairing memory consolidation) prompted the American Geriatrics Society to add diphenhydramine to the Beers Criteria list of medications to avoid in older adults. The finding remains one of the most consequential pieces of evidence in the ongoing reassessment of anticholinergic medications.